23rd December 2016

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

We are forwarding herewith press release titled as "Cipla's Flagship Product Sereflo™ Receives Final Approval from UK MHRA."

Thank you,

Yours faithfully,
For Cipla Limited

M. A. Sanghvi

Mital Sanghvi
Company Secretary

Encl: as above

Press Release

Cipla's Flagship Product Sereflo™ Receives Final Approval from UK MHRA

Mumbai, December 23, 2016: Cipla Ltd, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, has yielded a final approval for its lead MDI product Fluticasone + Salmeterol (Sereflo™) from UK MHRA for its partner in the UK.

Sereflo™, 25 mcg/125 mcg & 25 mcg/250 mcg are generic equivalent to GlaxoSmithKline's Seretide® Inhalers and are indicated for Asthma treatment.

Seretide® Inhaler, for the aforementioned strengths, had UK sales of approximately $278M for the 12 month period ending June 2016, according to IMS Health. Cipla's Sereflo™ will be launched in the UK through a partner in the coming weeks.

Commenting on the approval **Umang Vohra, MD and Global CEO Cipla Ltd**., said, "We are extremely pleased with the approval of Sereflo™ in the UK. This is a testament of Cipla's relentless efforts in the respiratory field for over a decade. This reinforces Cipla's commitment to make a difference in the life of patients with its innovative products. Sereflo™ will help patients with moderate to severe asthma breathe better."

About Cipla Ltd.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. In the last 80+ years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla's research and development focuses on developing innovative products and drug delivery systems.

Media Contacts:
Corporate Communications
Pallavi Golar
E Mail: pallavi.golar@cipla.com

Investor Relations
Alpesh Dalal
E-Mail: Investor.Relations@cipla.com